![]() ![]() Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders. Iwayama H, Ishihara N, Kawahara K, et al. Please see the original reference for a full list of disclosures. Study limitations included small sample size of patients with NMDs, lack of confirmation of vaccination site via ultrasound, and short follow-up period.ĭisclosures: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. The diluent contains killed antigens for canine coronavirusVaccine-leptospira canicola-grippotyphosa-icterohaemorrhagiae-pomona. They concluded that “Although BNT162b2 is administered by intramuscular injection, it appears to be effective and safe in patients with NMDs.” Spectra 10 vaccine is a combination of immunogenic attenuated strains of canine distemper,Canine adenovirus type 2 (cav-2), canine parainfluenza, and canine parvovirus type 2b,Propagated in cell line tissue cultures. Canine Spectra 10 is for the subcutaneous vaccination of healthy dogs 6 weeks of age or older as an aid in the prevention of disease caused by canine distemper, infectious canine hepatitis, canine adenovirus type 2, canine coronavirus, canine parainfluenza, canine parvovirus (CPV), Leptospira canicola, Leptospira. “Antibody titers in patients with NMDs were similar to those of healthy controls and there was no difference in the percentage of adverse reactions to BNT162b2 between the NMDs group and healthy controls,” the researchers stated. In contrast, participants in the control group experienced more injection site reactions and used more analgesics after the second vaccine than patients with NMDs ( P <.0001 P =.0252, respectively).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |